Home > In process > Associations of anticholinergic burden of medication with cognitive decline and longitudinal brain atrophy in the Alzheimer's disease spectrum. > print

001     285730
005     20260320144947.0
024 7 _ |a 10.3389/fnagi.2026.1751326
|2 doi
024 7 _ |a pmid:41853467
|2 pmid
024 7 _ |a pmc:PMC12992049
|2 pmc
037 _ _ |a DZNE-2026-00287
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 0
|e First author
|u dzne
245 _ _ |a Associations of anticholinergic burden of medication with cognitive decline and longitudinal brain atrophy in the Alzheimer's disease spectrum.
260 _ _ |a Lausanne
|c 2026
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1774014284_12448
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Anticholinergic side effects of pharmacological treatment are a risk factor for cognitive decline in older people. Here, we aimed to assess the effect of anticholinergic burden of treatment on longitudinal rates of cognitive change and atrophy in functionally related brain regions in people from the Alzheimer's disease (AD) spectrum.We determined associations of anticholinergic burden of pharmacological treatment with rates of global cognition, episodic memory and executive function decline as well as basal forebrain and hippocampus atrophy in participants of the memory clinic based DELCODE cohort, spanning the range from cognitively normal through subjective cognitive decline, mild cognitive impairment and AD dementia. We had 794 cases with neuropsychological outcomes, and a subset of 703 cases with MRI outcomes. Effects were assessed using mixed effect models in a Bayesian framework using prior-insensitive cross-validated Bayes factors (CV-BF) and parameter estimates.We found moderate evidence for an association of anticholinergic burden with baseline levels of cognitive impairment for the PACC5 as a global cognitive function score (CV-BF = 9.0) with more impairments with higher burden, but not with basal forebrain and hippocampus volumes, and weak evidence for an association of anticholinergic burden with longitudinal rates of change in the trail-making test B as an executive function score (CV-BF = 2.5), but not for other cognitive scores and not for brain volumes.In the presence of prodromal or manifest AD, in a memory clinic-based cohort anticholinergic burden had only a modest effect on cognitive decline and no effect on atrophy in brain regions that are related to the cholinergic system.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a MRI
|2 Other
650 _ 7 |a cholinergic basal forebrain
|2 Other
650 _ 7 |a hippocampus
|2 Other
650 _ 7 |a treatement
|2 Other
700 1 _ |a Grazia, Alice
|0 P:(DE-2719)9001307
|b 1
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 2
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 3
|u dzne
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 4
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 5
|u dzne
700 1 _ |a Bartels, Claudia
|0 P:(DE-2719)9000444
|b 6
700 1 _ |a Schott, Björn Hendrik
|0 P:(DE-2719)2814326
|b 7
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 8
|u dzne
700 1 _ |a Duezel, Emrah
|0 P:(DE-2719)2000005
|b 9
|u dzne
700 1 _ |a Yakupov, Renat
|0 P:(DE-2719)2812398
|b 10
|u dzne
700 1 _ |a Buerger, Katharina
|0 P:(DE-2719)2811351
|b 11
|u dzne
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 12
|u dzne
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 13
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 14
|u dzne
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 15
|u dzne
700 1 _ |a Peltner, Jonas
|0 P:(DE-2719)9002192
|b 16
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 17
|u dzne
700 1 _ |a Haenisch, Britta
|0 P:(DE-2719)2810511
|b 18
|e Last author
|u dzne
773 _ _ |a 10.3389/fnagi.2026.1751326
|g Vol. 18, p. 1751326
|0 PERI:(DE-600)2558898-9
|p 1751326
|t Frontiers in aging neuroscience
|v 18
|y 2026
|x 1663-4365
856 4 _ |u https://pub.dzne.de/record/285730/files/DZNE-2026-00287.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285730/files/DZNE-2026-00287.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2000026
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-2719)9001307
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 3
|6 P:(DE-2719)2811122
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2814326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2812398
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811351
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2812234
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)9002192
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2810511
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 2
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT AGING NEUROSCI : 2022
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2025-05-13T11:21:24Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2025-05-13T11:21:24Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2025-05-13T11:21:24Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2025-05-13T11:21:24Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-10
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-11-10
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-10
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-10
920 1 _ |0 I:(DE-2719)1013010
|k AG Hänisch
|l Pharmacoepidemiology
|x 0
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 1
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 2
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 3
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 4
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 5
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 6
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 7
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 8
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 9
920 1 _ |0 I:(DE-2719)1011103
|k AG Spottke
|l Clinical Research Platform (CRP)
|x 10
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 11
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1013010
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)1011103
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21